

# Orgenesis

10:58 03 Apr 2019

## Orgenesis showcases publication of diabetes study in Stem Cell Research and Therapy Journal

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, on Wednesday announced the publication of a promising diabetes study entitled "The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells" in the February issue of the Journal of Stem Cell Research and Therapy.

Orgenesis points out that insulin-dependent diabetes is a disorder that could, in theory, be cured by functional pancreatic islets and the implantation of autologous insulin-producing cells.

Results of the study, which focused on insulin-dependent diabetes and was carried out in mice, show that the co-implantation of mesenchymal stem cells (MSCs) and endothelial colony forming cells (ECFCs) with autologous insulin-producing cells led to the doubling of survival rates and a three-fold increase in insulin production.

**READ:** Orgenesis stock climbs after it posts 139% expansion in gross profit for fiscal 2018 on revenue surge

In a statement, Professor Sarah Ferber, chief scientific officer of Orgenesis, praised the study for offering proof that the transdifferentiation process, which is the conversion of one adult tissue or cell into another type of cell, works.

"In this study, we were able to uncover that vasculature is an important factor in generating regenerative properties and is a fitting approach for the treatment of diabetes," explained Ferber. "Vasculature enacts cell-to-cell communication, inducing a change of the maturation of insulin producing cells and their survival upon implementation."

Orgenesis is a biotech company focused on cell and gene therapies.

The Germantown, Maryland-based company's goal is to utilize its know-how and intellectual property to advance new autologous cell therapies to a clinical stage and enable point-of-care cell therapy development and services.

Two of the most common types of stem cell transplants are autologous and allogeneic transplants. Both kinds of stem cell transplantations are a common treatment option for cancers such as leukemia, lymphoma, and multiple myeloma.

An autologous transplant uses a person's own stem cells, while an allogeneic transplant uses stem cells from a donor whose human leukocyte antigens (HLA) are acceptable matches to the patient's.


Orgenesis shares held steady at \$5.20 in morning trade on Wednesday

Contact Ellen at [ellen@proactiveinvestors.com](mailto:ellen@proactiveinvestors.com)

**Price:** 3.97

**Market Cap:** \$72.89 m

### 1 Year Share Price Graph



April 2019    October 2019    April 2020

### Share Information

**Code:** ORGS

**Listing:** NASDAQ

52 week	High	Low
	6.36	2.35

**Sector:** Pharma & Biotech

**Website:** [www.orgenesis.com](http://www.orgenesis.com)

### Company Synopsis:

*Orgenesis is a vertically-integrated biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. The Company's MaSTherCell subsidiary is a global Contract Development and Manufacturing Organization (CDMO).*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).